Abstract
Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally administered gefitinib. We analyzed the pharmacokinetic data of gefitinib in this patient and found that that gefitinib was safe under these conditions.